Integer Holdings CorpITGR

Integer Holdings Corp is a contract manufacturer of medical devices tucked inside the glossy story of “innovation.” The real business is turning metal into guidewires, coils, and implantable pulse-generator shells that end up inside dialysis patients, aneurysm coils, and hearing implants. The company’s own product pages read like a museum exhibit: “Combined Devices: Your Product Lifecycles from Concept to Completion,” it declares, while the balance sheet quietly reports $284.5 million of inventory-enough to keep the factory humming even if every customer order disappears tomorrow. (source: Products section, https://www.integer.net/products/combined-devices/default.aspx; Inventory, Net: $284.5M, 10-Q, period ending 2026-04-03, https://www.sec.gov/Archives/edgar/data/1114483/000095012326005512/filing_1097391.htm)

The last quarter’s revenue was $439.6 million, which sounds substantial until you realise it is the sum of thousands of small orders for parts that are mostly invisible to end-users. The firm reports $16.5 million of net income, $24.7 million of operating cash flow, and a cash pile of $8.1 million-numbers that look healthy until you notice $24 million of capex sucked up the cash like a hungry aspirator. The company’s own market guide lists “neuromodulation,” “guidewires,” and “IPG components” as growth vectors, but the evidence shows no blockbuster approvals, no marquee customer wins, and no revenue line that jumps off the 10-Q. (source: Revenue from Contract with Customer, Excluding Assessed Tax: $439.6M, Net Income Attributable to Parent: $16.5M, Operating Income: $31.9M, Cash and Cash Equivalents, at Carrying Value: $8.1M, Payments to Acquire Property, Plant, and Equipment: $24.0M, 10-Q, period ending 2026-04-03, https://www.sec.gov/Archives/edgar/data/1114483/000095012326005512/filing_1097391.htm)

The filings also show a company that is quietly capital-intensive: inventory rose by $32.4 million in the quarter, which is either prudent hedging or the first sign of a sales force that is overpromising and under-delivering. The board, meanwhile, has been treated to six Form 4 filings in July alone, as insiders trimmed exposure. The optics of “value creation” look thinner when the cash position is $8.1 million and the factory floor is swallowing $24 million to keep the drills turning. (source: Increase (Decrease) in Inventories: $32.4M, 10-Q, period ending 2026-04-03, https://www.sec.gov/Archives/edgar/data/1114483/000095012326005512/filing_1097391.htm; ITGR 4 (2026-07-10), https://www.sec.gov/Archives/edgar/data/1114483/000214480526000004/xslF345X06/wk-form4_1783722766.xml)

For context on the product side, Integer’s neuromodulation page promises “devices for patients with hearing loss & epilepsy,” while the IPG components page promises “end-to-end product solutions.” The evidence does not show which customer or regulator approved these claims, nor does it quantify the revenue tied to them. The company’s own product index lists “guidewires,” “combined devices,” and “IPG components,” but the 10-Q does not break out segment revenue, so the reader must trust the marketing headline rather than the filing. (source: Neuromodulation, https://www.integer.net/markets/neuromodulation/default.aspx; IPG Components, https://www.integer.net/products/ipg-components/default.aspx; Products A-Z, https://www.integer.net/products/products-a-z/default.aspx; 10-Q, period ending 2026-04-03, https://www.sec.gov/Archives/edgar/data/1114483/000095012326005512/filing_1097391.htm)

What changed this week is the insider selling cadence: six Form 4s in July, each one a silent vote of confidence in the stock’s future and a reminder that “long-term value” can look like “exit” when the cash position is thin. The company’s own 8-K from June 26, 2026, does not disclose any material event beyond routine officer changes, leaving investors to parse Form 4s for clues about insider intent. (source: ITGR 8-K (2026-06-26), https://www.sec.gov/Archives/edgar/data/1114483/000111448326000024/gb-20260624.htm; ITGR 4 (2026-07-01), https://www.sec.gov/Archives/edgar/data/1114483/000172695526000007/xslF345X06/wk-form4_1782936808.xml)

The only thing the evidence does not show is a single customer, product, or approval that would re-rate the shares. Until Integer breaks out revenue by segment or discloses a marquee design win, the plate remains full of marketing copy and light on hard numbers. (source: SEC companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001114483.json)